Asian Pacific Journal of Cancer Prevention

  • 제16권10호
  • /
  • Pages.4169-4172
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Hesa-A Improves Clinical Outcome of Oral Carcinoma by Affecting p53 Gene Expression in vivo

  • Abbasi, Mehran Mesgari (Drug Applied Research Center, Tabriz University of Medical Sciences) ;
  • Helli, Sanaz (Dental and Periodontal Research Center, Tabriz University of Medical Sciences) ;
  • Monfaredan, Amir (Department of Hematology, Faculty of Medicine, Tabriz Branch Islamic Azad University) ;
  • Jahanban-Esfahlan, Rana (Student Research Committee, Tabriz University of Medical Sciences)
  • 발행 : 2015.06.03
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Oral carcinoma (OC) remains as one of the most difficult malignancies to cure. Hesa-A is an Iranian herbal-marine compound that has shown promising anti-tumor properties on various human cancer cells, although the mechanisms of action remain to be addressed. This study was conducted to evaluate the effect of two doses of Hesa-A on mRNA expression of p53 as a main prognosticator of OC. Materials and Methods: 60 rats were randomly divided into 5 groups of 12 animals each. Rats in carcinoma groups received 0, 250 and 500 mg/kg body weight of Hesa-A three times a day. The two other groups considered as treated and untreated healthy groups. At the end of experiment, animals were sacrificed and tongue tissues subjected to H and E staining and real time PCR. Results: Our results indicated that compared to healthy group, p53 over expressed ~ 40% in untreated carcinoma group. After treatment with 250mg/kg and 500mg/kg body weights of Hesa-A, p53 level dropped by 53.4% and 13.6 %, respectively, compared to untreated carcinoma group (p<0.05, p<0.0001). Moreover, there was a significant relation between p53 mRNA content and observed pathological changes in studied groups (p<0.05). Conclusions: These data provide insights into the mechanism(s) by which Hesa-A improves clinical outcome of oral carcinoma by modulation of p53 expression.

키워드

참고문헌

  1. Abbasi MM, Jahanban-Esfahlan R, Monfaredan A, et al (2014a). Oral and IV dosages of doxorubicin-methotrexate loadednanoparticles inhibit progression of oral cancer by downregulation of matrix methaloproteinase 2 expression in vivo. Asian Pac J Cancer Prev, 15, 10705-11.
  2. Abbasi MM, Khiavi MM, Monfaredan A, et al (2014b). DOXMTX- NPs augment p53 mRNA expression in OSCC model in rat: effects of IV and oral routes. Asian Pac J Cancer Prev, 15, 8377-82. https://doi.org/10.7314/APJCP.2014.15.19.8377
  3. Abbasi MM, Monfaredan A, Hamishehkar H, et al (2014c). New formulated "DOX-MTX-loaded nanoparticles" downregulate HER2 gene expression and improve the clinical outcome in OSCCs model in rat: the effect of IV and oral modalities. Asian Pac J Cancer Prev, 15, 9355-60. https://doi.org/10.7314/APJCP.2014.15.21.9355
  4. Abbasi MM, Monfaredan A, Hamishehkar H, et al (2014d). Novel DOX-MTX nanoparticles improve oral SCC clinical outcome by down regulation of lymph dissemination factor VEGF-C expression in vivo: oral and IV modalities. Asian Pac J Cancer Prev, 15, 6227-32. https://doi.org/10.7314/APJCP.2014.15.15.6227
  5. Abusail M, Dirweesh AM, Salih RA, et al (2013). Expression of EGFR and p53 in head and neck tumors among sudanese patients. Asian Pac J Cancer Prev, 14, 6415-8 https://doi.org/10.7314/APJCP.2013.14.11.6415
  6. Ahmadi A, Habibi G, Farrokhnia M (2010a). Anticancer effects of HESA-A: An herbal marine compound. Chin J Integr Med, 16, 366-7. https://doi.org/10.1007/s11655-010-0517-x
  7. Ahmadi A, Mohagheghi M, Karimi M, et al (2009). Anticancer effects of HESA-A in patients with metastatic colon cancer. Integr. Cancer Ther, 8, 71-4. https://doi.org/10.1177/1534735408327995
  8. Ahmadi A, Mohagheghi M, Karimi M, et al (2010b). Therapeutic effects of HESA-A in patients with end-stage metastatic cancers. Integr. Cancer Ther, 9, 32-5. https://doi.org/10.1177/1534735409357934
  9. Ahmadi A, Mohagheghi MA, Fazeli MS, et al (2005). HESA-A: new treatment for breast cancer and choroidal metastasis. Med Sci Monit, 11, 300-3.
  10. Jahanban Esfahlan R, Zarghami N, Jahanban Esfahlan A, et al (2011a). The possible impact of obesity on androgen, progesterone and estrogen receptors (ERa and ERb) gene expression in breast cancer patients. breast cancer (Auckl), 227-37.
  11. Jahanban Esfahlan R, Zarghami N, Rahmati-Yamchi M, et al (2011b). Quantification of steroid receptors gene expression in breast cancer patients: possible correlation with serum level of adipocytokines. J Cancer Therapy, 2, 659-65. https://doi.org/10.4236/jct.2011.25088
  12. Jahanban Esfahlan R, Zarghami N, Valiyari S, et al (2012). Adiponectin can affect ER signaling in obese breast cancer patients. J Cancer Therapy, 3, 115-21 https://doi.org/10.4236/jct.2012.31015
  13. Mehdipour M, Taghavi Zenouz A, Mesgari Abbasi M, et al (2013b). Evaluation of the effect of two systemic doses of HESA-A on prevention of induced tongue neoplasm in rats. J Dent Res Dent Clin Dent Prospects, 7, 218-24.
  14. Muhammmadnejad S, Zendehdel K, Mazaheri Z, et al (2014). Assessment of selective growth inhibitory effects of HESA-A on some human neoplastic cell lines. Breast Cancer: Basic and Clinical Res, 6.
  15. Valiyari S, Jahanban-Esfahlan R, Zare Shahneh F, et al (2013). Cytotoxic and apoptotic activity of Scrophularia oxysepala in MCF-7 human breast cancer cells. Toxicol Environmental Chem, 95, 1208-20. https://doi.org/10.1080/02772248.2013.854362
  16. Zwetyenga N, Majoufre-Lefebvre C, Siberchicot F, et al (2003). [Squamous-cell carcinoma of the tongue: treatment results and prognosis]. Rev Stomatol Chir Maxillofac, 104, 10-7.